pharma · Phenylketonuria · Achondroplasia
BioMarin Pharmaceutical Australia Pty Ltd
BioMarin Pharmaceutical Australia is a pharma organization headquartered in San Rafael, USA. Primary therapeutic focus areas include Phenylketonuria, Achondroplasia, Duchenne Muscular Dystrophy, Phenylketonuria (PKU), Hy
Phase 3 · small molecule · Hypochondroplasia
Voxzogo (vosoritide) is a subcutaneous injection approved for hypochondroplasia, a genetic skeletal dysplasia characterized by short stature. The drug is a small-molecule therapeutic developed by BioMarin Pharmaceutical Australia Pty Ltd and is currently in Phase 3 development as a long-term extension study. Voxzogo ha
Internal code 111-308
Voxzogo (vosoritide) is a subcutaneous injection approved for hypochondroplasia, a genetic skeletal dysplasia characterized by short stature. The drug is a small-molecule therapeutic developed by BioMarin Pharmaceutical Australia Pty Ltd and is currently in Phase 3 development as a long-term extension study. Voxzogo has achieved regulatory approval in Australia (May 2023), the European Union (November 2025), and the United States, indicating successful completion of earlier development phases and market authorization across major regions.
The program (internal code 111-308) represents BioMarin's strategic focus on rare genetic bone disorders. The latest disclosed milestone is a Phase 3 open-label, long-term extension study designed to evaluate safety and efficacy in children with hypochondroplasia. This extension trial follows successful pivotal studies and supports post-approval surveillance and label optimization.
Voxzogo is classified within the musculo-skeletal system therapeutic class (M05) and is administered via subcutaneous injection. The drug has been listed on the Australian PBS (Pharmaceutical Benefits Scheme) under codes 13270K, 13274P, and 13275Q, indicating reimbursement coverage. In the EU, BioMarin International Limited holds marketing authorization (EMEA/H/C/005475). The competitive landscape includes other musculo-skeletal therapies such as CRYSVITA (for hypophosphatemic rickets), bone-targeting agents, and osteoporosis treatments, though Voxzogo's specific mechanism and indication differentiate its positioning.
Hypochondroplasia is a rare genetic skeletal dysplasia with limited treatment options, creating a significant unmet medical need. Affected children experience growth restriction and skeletal abnormalities that impact quality of life and functional outcomes. The rarity of the condition and the absence of disease-modifying therapies prior to vosoritide's development underscore the clinical importance of this program.
Voxzogo's approval across Australia, the EU, and the US demonstrates successful regulatory validation and market access in three major healthcare systems. The inclusion on the Australian PBS indicates health economic acceptance and reimbursement support, a critical factor for rare disease commercialization. This multi-region approval strategy positions BioMarin to capture market share across geographically diverse patient populations.
The competitive landscape for hypochondroplasia treatment is limited. CRYSVITA (burosumab), approved for hypophosphatemic rickets, addresses a related but distinct skeletal disorder. Other competitors listed (ibandronic acid, denosumab, alendronate) target osteoporosis and bone loss rather than genetic skeletal dysplasias, indicating minimal direct competition in the hypochondroplasia space. This therapeutic isolation enhances Voxzogo's commercial potential and market exclusivity.
The ongoing Phase 3 long-term extension study supports post-approval data generation, label expansion potential, and pediatric indication optimization. Long-term safety and efficacy data in children are commercially valuable for establishing durability claims and supporting clinical practice adoption among pediatric specialists.
Drug Class: Musculo-skeletal system therapeutic (ATC M05); rare genetic bone disorder treatment.
Modality: Small-molecule injection.
Route of Administration: Subcutaneous injection.
Mechanism of Action: Not yet disclosed in available facts.
Target: Not yet disclosed in available facts.
Brand Name: Voxzogo.
International Nonproprietary Name (INN): Vosoritide.
Formulations: Three approved strengths: 0.4 mg, 0.56 mg, and 1.2 mg powder and solvent for solution for injection.
First Approval: Australia, May 1, 2023 (TGA listing); European Union, November 17, 2025 (EMA authorization EMEA/H/C/005475); United States (FDA NDA 214938, date not yet disclosed).
Patent Status: Not yet disclosed.
Related Therapies: CRYSVITA (burosumab) for hypophosphatemic rickets; other bone-targeting agents including bisphosphonates and denosumab for osteoporosis and metabolic bone disease.
Also known as: HCH
Prevalence: Point prevalence: 1-9 / 100 000 (Worldwide) — source: Orphanet, validated.
Hypochondroplasia is characterized by disproportionate short stature, mild lumbar lordosis and limited extension of the elbow joints.
ClinicalTrials.gov lists 11 registered studies for Hypochondroplasia (AACT aggregate).
Phase breakdown: NA (5), PHASE2 (3), PHASE3 (2), PHASE2/PHASE3 (1)
Common investigational therapies:
Disease data sourced from MONDO Disease Ontology (MONDO:0007793), Orphanet — hypochondroplasia, NCT01111019, NCT01541306, NCT05328050, NCT06212947, NCT06410976, AACT (ClinicalTrials.gov aggregate), ClinicalTrials.gov, Open Targets Platform (CC BY 4.0).
TGA Approval (Australia)
Voxzogo approved and listed on Australian ARTG with PBS reimbursement codes 13270K, 13274P, 13275Q.
EMA Approval (European Union)
European Commission grants marketing authorization; BioMarin International Limited holds MAH; EMEA product number EMEA/H/C/005475.
FDA Approval (United States)
Voxzogo approved under NDA 214938; exact approval date not yet disclosed.
Phase 3 Long-Term Extension Study (Ongoing)
Open-label, long-term extension study evaluating safety and efficacy of vosoritide in children with hypochondroplasia; NCT identifier 2024-517238-16-00.
The competitive landscape for hypochondroplasia treatment is limited, with Voxzogo occupying a relatively isolated therapeutic position. CRYSVITA (burosumab, Kyowa Kirin Australia Pty Ltd), approved for hypophosphatemic rickets, represents the closest competitor in the rare skeletal dysplasia space, though it targets a distinct genetic disorder with different pathophysiology.
Other approved competitors listed—including ibandronic acid (Teva Pharma GmbH), denosumab (Amgen's Prolia/Evenity; Intas as Vysribli), alendronate (Mylan, MSD), and other bone-targeting agents (Corora, Aclasta, Osseor, Inductos, Osigraft)—primarily address osteoporosis, bone loss, and metabolic bone disease in adult populations. These therapies do not directly compete in the pediatric hypochondroplasia indication, as they target different disease mechanisms and patient demographics.
Voxzogo's competitive advantage derives from its specificity for hypochondroplasia, a rare genetic condition with no prior disease-modifying treatment options. The absence of direct competitors in this indication, combined with multi-region regulatory approval and PBS reimbursement in Australia, positions Voxzogo as the market leader in its niche. Future competitive pressure may emerge if other sponsors develop alternative therapies for hypochondroplasia, but no such programs are disclosed in the current facts.
| Therapy | Company | Mechanism | Status |
|---|---|---|---|
| IBANDRONIC ACID SANDOZ | Teva Pharma GmbH | — | approved |
| CORORA | Amgen | — | approved |
| ACLASTA | Apotex Pty Ltd | — | approved |
| CRYSVITA | KYOWA KIRIN AUSTRALIA PTY LTD | — | approved |
| OSIGRAFT | — | — | approved |
| EVENITY | Amgen | — | approved |
| OSSEOR | — | — | approved |
| ALENDRONIC ACID / COLECALCIFEROL MYLAN | — | — | approved |
| VYSRIBLI (PREVIOUSLY DENOSUMAB INTAS) | — | — | approved |
| VANTAVO (PREVIOUSLY ALENDRONATE SODIUM AND COLECALCIFEROL, MSD) | — | — | approved |
| INDUCTOS | — | — | approved |
| Voxzogo 1.2 mg powder and solvent for solution for injection, powder and solvent for solution for injection, Voxzogo 0.56 mg powder and solvent for solution for injection | BioMarin Pharmaceutical Australia Pty Ltd | small_molecule | phase_3 |
| VOSORITIDE | — | Atrial natriuretic peptide receptor B binding agent | Phase 3 |
| SOMATROPIN | — | Growth hormone receptor agonist | Phase 2 |
Additional associated therapies sourced from Open Targets Platform (CC0), linked to NovaPharmaNews drug profiles where matched.
Australia (TGA): Voxzogo approved and listed on the Australian Register of Therapeutic Goods (ARTG) effective May 1, 2023. PBS reimbursement codes assigned: 13270K, 13274P, 13275Q. Sponsor: BioMarin Pharmaceutical Australia Pty Ltd. Evidence available at https://www.tga.gov.au/resources/artg?keywords=vosoritide.
European Union (EMA): Marketing authorization granted November 17, 2025. Marketing Authorization Holder (MAH): BioMarin International Limited. EMA product number: EMEA/H/C/005475. Evidence available at https://www.ema.europa.eu/en/medicines/human/EPAR/voxzogo.
United States (FDA): Voxzogo approved under New Drug Application (NDA) 214938. Sponsor: BIOMARIN PHARM. Exact approval date not yet disclosed. Evidence available via FDA drug database (https://open.fda.gov/apis/drug/drugsfda/).
Japan (PMDA): Regulatory status not yet disclosed.
China (NMPA): Regulatory status not yet disclosed.
Expected Loss of Exclusivity (LOE): Not yet disclosed.
Voxzogo (vosoritide) is approved for the treatment of hypochondroplasia, a rare genetic skeletal dysplasia characterized by short stature and skeletal abnormalities in children.
Yes. Voxzogo is approved in Australia (TGA, May 2023), the European Union (EMA, November 2025), and the United States (FDA, under NDA 214938; exact date not yet disclosed).
Voxzogo is administered as a subcutaneous injection. Three strengths are available: 0.4 mg, 0.56 mg, and 1.2 mg powder and solvent for solution for injection.
BioMarin Pharmaceutical Australia Pty Ltd is the sponsor and developer. BioMarin International Limited holds the European marketing authorization.
The specific mechanism of action is not yet disclosed in available regulatory or clinical documentation.
The molecular target is not yet disclosed in available facts.
Pivotal trials supporting approval are not detailed in the current facts. An ongoing Phase 3 long-term extension study (NCT 2024-517238-16-00) is currently evaluating safety and efficacy in children with hypochondroplasia.
Yes. Voxzogo is listed on the Australian Pharmaceutical Benefits Scheme (PBS) under reimbursement codes 13270K, 13274P, and 13275Q, indicating coverage and reimbursement support.
Hypochondroplasia is a rare genetic skeletal dysplasia that causes short stature and skeletal abnormalities. It is a genetic bone disorder with limited treatment options prior to vosoritide's development.
No direct competitors for hypochondroplasia are disclosed. CRYSVITA (burosumab) treats a related but distinct skeletal disorder (hypophosphatemic rickets). Other approved competitors target osteoporosis and bone loss, not genetic skeletal dysplasias.
Voxzogo is approved in Australia, the EU, and the US. A Phase 3 long-term extension study is ongoing to evaluate continued safety and efficacy in children with hypochondroplasia.
Voxzogo is classified within the musculo-skeletal system therapeutic class (ATC M05), which includes treatments for bone and joint disorders.
Three strengths are approved: 0.4 mg, 0.56 mg, and 1.2 mg, each supplied as powder and solvent for solution for injection.
Voxzogo was approved and listed on the Australian ARTG on May 1, 2023.
Voxzogo received European Commission marketing authorization on November 17, 2025, under EMA product number EMEA/H/C/005475.
Voxzogo is approved by the FDA under NDA 214938. The exact approval date is not yet disclosed in available facts.
Yes. An ongoing Phase 3 open-label long-term extension study (NCT 2024-517238-16-00) is evaluating the long-term safety and efficacy of vosoritide in children with hypochondroplasia.
111-308 → Drug → Target → Indication → Company → Trials → Competitors
Strategic Positioning: BioMarin's development of Voxzogo reflects a focused strategy in rare genetic skeletal dysplasias, a market segment with high unmet medical need and limited competition. Multi-region approval (Australia, EU, US) demonstrates successful regulatory execution and positions the company for global commercialization in a niche indication.
Post-Approval Development: The ongoing Phase 3 long-term extension study (NCT 2024-517238-16-00) indicates BioMarin's commitment to generating durability and safety data beyond initial approval. This strategy supports label optimization, clinical practice adoption, and potential pediatric indication expansion.
Reimbursement and Market Access: PBS listing in Australia with three reimbursement codes signals successful health economic negotiation and payer acceptance. This is critical for rare disease commercialization, as reimbursement barriers often limit patient access and revenue potential.
Competitive Moat: The absence of direct competitors in hypochondroplasia treatment creates a therapeutic monopoly. CRYSVITA's presence in related skeletal dysplasias does not directly threaten Voxzogo's market position, though it demonstrates payer familiarity with rare bone disorder treatments and may facilitate Voxzogo's adoption.
Future Catalysts: (1) Completion and publication of Phase 3 long-term extension data; (2) potential label expansions (e.g., adolescent or adult indications); (3) regulatory approvals in additional markets (Japan, China); (4) commercial uptake metrics and patient enrollment data; (5) emergence of competing therapies or alternative treatment modalities.
Commercial Implications: Hypochondroplasia is a rare condition with a limited patient population, constraining peak sales potential. However, high unmet medical need, multi-region approval, and reimbursement support suggest sustainable commercial viability within the rare disease market segment.
Concise, citable answers optimized for AI answer engines.
Intelligence compiled from public regulatory and clinical sources (FDA, EMA, ClinicalTrials.gov and company disclosures). Figures may be editorial or analyst estimates; verify against primary sources before relying on them.